MMA Asset Management’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$414K Sell
7,094
-5,304
-43% -$313K 0.13% 140
2026
Q2
$695K Sell
12,398
-1,132
-8% -$58.9K 0.22% 90
2026
Q1
$649K Sell
13,530
-152
-1% -$6.66K 0.23% 83
2025
Q4
$529K Sell
13,682
-127
-0.9% -$4.84K 0.19% 100
2025
Q3
$487K Buy
13,809
+4,960
+56% +$180K 0.16% 111
2025
Q2
$319K Buy
+8,849
New +$293K 0.12% 127

Other funds holding RPRX

MMA Asset Management's RPRX Position: Q3 2026 in Review

MMA Asset Management reduced its Royalty Pharma (RPRX) stake by 43% in Q3 2026, selling an estimated $313K and leaving 7,094 shares worth $414K. The position accounts for 0.13% of the portfolio, ranked #140.

MMA Asset Management first reported a position in RPRX in Q2 2025 and has held it in 6 quarters since. The position peaked at $695K in Q2 2026. 707 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • MMA Asset Management held 7,094 shares of Royalty Pharma worth $414K as of Q3 2026.
  • MMA Asset Management sold 5,304 Royalty Pharma shares in Q3 2026, an estimated $313K.
  • Royalty Pharma made up 0.13% of MMA Asset Management's portfolio in Q3 2026, its #140 holding.
  • MMA Asset Management first reported a position in Royalty Pharma in Q2 2025 and has held it in 6 quarters since.
  • MMA Asset Management's Royalty Pharma position peaked at $695K in Q2 2026.
  • 707 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on MMA Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.